MELBOURNE, Australia and SAN FRANCISCO, March 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David...
News Ticker
- [ March 25, 2023 ] 89bio to net $275M from stock offering; Assembly Bio to pause work on one HBV inhibitor program News
- [ March 25, 2023 ] Q&A: BioCina’s new CEO Mark Womack on the CDMO he says is ‘worth traveling over’ News
- [ March 25, 2023 ] SLAC’s Sadasivan Shankar on sustainable computing News
- [ March 24, 2023 ] Scientist – Radiant Systems Inc – South San Francisco, CA San Francisco Biotech Jobs
- [ March 24, 2023 ] SENIOR RESEARCH ASSOCIATE/ASSOCIATE SCIENTIST* – CARGO-Therapeutics – San Francisco, CA San Francisco Biotech Jobs
Copyright © 2022 Biotech Networks, LLC
